PRV111
AssetAlso cisplatin, PRV211, Cisplatin Transmucosal System, Intraoperative Cisplatin System
Platinum-based DNA crosslinking agent formulated for transmucosal or intraoperative local delivery.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- DNA damage response
- 4
- Indications
- 2,008
- Trials
- 1
- Developer
Indications
4Early-stage oral cancer
Phase 2, prnewswire.com, 5 Oct 2026
Oral cancer
Phase 2, prnewswire.com, 5 Oct 2026
Oral carcinoma in situ
Phase 2, prnewswire.com, 5 Oct 2026
1 more
In the full profile
- Targets and what it contains4
- Owner and partners1
- Trials2,008
- Evidence for its targets4
- Competitors12
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.